At the molecular level, TERT promoter mutations represent the most frequent early “gatekeeper” event, with additional alterations in CTNNB1, TP53, and epigenetic regulators (BAP1, ARID1A/B, ARID2) further driving tumor progression. Here, ARID2 is linked to neoplasm.